目的：通过UPLC-ESI-MS n 方法定性分析糖痹康颗粒（TBK）的入血成分，初步阐明糖痹康颗粒的药效物质基础。方法：采用UPLC-LTQ-Orbitrap高分辨液质联用仪，在电喷雾离子源的正、负离子模式下，对空白血清、糖痹康颗粒经大鼠给药后的含药血清进行检测。根据离子碎片信息，偶电子规律，氮规则等并结合相应参考文献，定性分析并鉴定入血成分。结果：糖痹康颗粒灌胃给药后，在大鼠血清中发现15个入血成分，其中13个是以原型成分被吸收，其余2个可能为代谢产物。结论：糖痹康入血成分是各组方药味配伍后共同作用的结果，在大鼠血清中，多数成分已经被大鼠代谢吸收，少数以原型成分吸收。本实验为糖痹康颗粒的药效物质基础和体内代谢研究提供参考。

Through comprehensively characterizing components in blood after oral administration of Tang- Bi- Kang(TBK) granules by UPLC-ESI-MS n , this study was aimed to explain the pharmaceutical material basis of TBK initially.UPLC-LTQ-Orbitrap was used under both positive and negative ion modes of electrospray ionization. The blank serum and rat serum after oral administration of TBK were analyzed. Components in rat serum were identified and characterized based on ion fragment information, evenelectron law, nitrogen rule and so on. Reference data was used to establish the UPLC-ESI-MS n method. The results showed that after oral administration of TBK granules, 15 components were detected in the serum, of which 13 components were taken as the prototype to blood and 2 metabolites. It was concluded that constituents of TBK granules in rat serum were generated from compatibility of all herbal medicines. In rat serum, most of the components had been absorbed by rat's metabolism; a few were absorbed as the prototype. This research provided references for pharmacodynamic material basis and metabolism of TBL granules in vivo.

科学技术部国家"重大新药创制"科技重大专项（2012ZX09102201-001）：治疗糖尿病周围神经病变药物糖痹康临床前研究，负责人：刘铜华；北京中医药大学创新团队-中医药干预糖尿病及其并发症研究团队（2011-CXTD-19），负责人：刘铜华。